X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
The net proceeds will be used to advance the clinical development of FHD-286, a selective, oral inhibitor of BRG1 and BRM, which is being evaluated in relapsed/refractory AML
Lead Product(s): FHD-286,Cytarabine
Therapeutic Area: Oncology Product Name: FHD-286
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: BVF Partners
Deal Size: $110.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering May 22, 2024
Details:
FHD-286 is a highly potent, selective, allosteric and orally available, small-molecule, enzymatic inhibitor of BRG1 and BRM, which is investigated for the treatment of relapsed and/or refractory acute myelogenous leukemia.
Lead Product(s): FHD-286,Cytarabine
Therapeutic Area: Oncology Product Name: FHD-286
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 31, 2023
Details:
FHD-286 is a highly potent, selective, allosteric and orally available, small-molecule, enzymatic inhibitor of BRG1 and BRM, which is investigated for the treatment of Metastatic Uveal Melanoma.
Lead Product(s): FHD-286
Therapeutic Area: Oncology Product Name: FHD-286
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 28, 2023
Details:
FHD-286 is a highly potent, selective, allosteric and orally available, small-molecule, enzymatic inhibitor of BRG1 and BRM. FDA has lifted the clinical hold on the Phase 1 monotherapy dose escalation study of FHD-286 in AML and MDS.
Lead Product(s): FHD-286
Therapeutic Area: Oncology Product Name: FHD-286
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 05, 2023
Details:
FHD-286 is a highly potent, selective, allosteric and orally available, small-molecule, enzymatic inhibitor of BRG1 and BRM. In preclinical studies, FHD-286 has shown anti-tumor activity for broad range of malignancies.
Lead Product(s): FHD-286
Therapeutic Area: Oncology Product Name: FHD-286
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 09, 2023
Details:
FHD-286 is a highly potent, allosteric and orally available, small-molecule, enzymatic inhibitor of BRG1 and BRM, two highly similar proteins that are the ATPases, or the catalytic engines of the BAF complex, one of the key regulators within the chromatin regulatory system.
Lead Product(s): FHD-286
Therapeutic Area: Oncology Product Name: FHD-286
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 05, 2022
Details:
New preclinical data will be presented on FHD-286, a potent and selective BRG1/BRM inhibitor, which is currently in Phase 1 clinical trials for metastatic uveal melanoma and for relapsed and/or refractory acute myelogenous leukemia and myelodysplastic syndrome.
Lead Product(s): FHD-286,Undisclosed
Therapeutic Area: Oncology Product Name: FHD-286
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2022
Details:
FHD-286 is a highly potent, selective, allosteric and orally available, small-molecule, enzymatic inhibitor of BRG1 and BRM, two highly similar proteins that are the ATPases, or the catalytic engines across all forms of the BAF complex.
Lead Product(s): FHD-286
Therapeutic Area: Oncology Product Name: FHD-286
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 21, 2022
Details:
FHD-286, a small-molecule, enzymatic inhibitor of BRG1 and BRM, two highly similar proteins that are ATPases, or catalytic engines of BAF complex, one of key regulators within chromatin regulatory system, in preclincial studies it demonstrates anti-tumor activity.
Lead Product(s): FHD-286
Therapeutic Area: Oncology Product Name: FHD-286
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 01, 2022
Details:
Foghorn is focused on drugging targets in the chromatin regulatory system. Its lead candidate FHD-286 is an allosteric ATPase inhibitor.
Lead Product(s): FHD-286
Therapeutic Area: Oncology Product Name: FHD-286
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Goldman Sachs & Co. LLC
Deal Size: $120.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering October 22, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
